Introduction: There is common statement, that schizophrenia patients are more likely to smoke comparing to the total world population.
The aim of the study: The aim of this article is to find out why do schizophrenic patients smoke, how does it affect them and what can be the cause of susceptibility to smoking.
Material and method: The research of the scientific articles was made on a database of PubMed and Google Scholar.
Description of the state of knowledge: Many different associations were found during the research such as these describing that patients with schizophrenia have up to two to five times higher risk of developing type II diabetes. Also patients with diagnosed schizophrenia are characterized by low neuronal activity of the frontal and temporal lobes of the brain. In post mortem studies in schizophrenic patients a decrease in the number of M1 and M2 receptors in the brain was found, mainly in the dorsal lateral part of the prefrontal cortex, hippocampus, striatum and cingulate cortex, and decreased number of nicotinic receptors in the hippocampus, thalamus, cingulate cortex and prefrontal cortex
The key process of undergoing of nicotine is the induction of the cytochrome P450 1A2 enzyme (CYP 1A2), thus increasing the metabolism of antipsychotic therapeutics, e.g. olanzapine, clozapine what explain why usage of nicotine is told to be self-treatment in schizophrenic people.
Summary: This article gathers scientific research on the relationship between schizophrenia and susceptibility among patients to smoking addiction and its impact on both mental and physical health. However, not all mechanisms are known yet.

schizophrenia disease; nicotine; tobacco; smoking

Janoutová J, Janácková P, Serý O, Zeman T, Ambroz P, Kovalová M, Varechová K, Hosák L, Jirík V, Janout V. Epidemiology and risk factors of schizophrenia. Neuro Endocrinol Lett. 2016;37(1):1-8.

Hofer A, Mizuno Y, Wartelsteiner F, Wolfgang Fleischhacker W, Frajo-Apor B, Kemmler G, Mimura M, Pardeller S, Sondermann C, Suzuki T, Welte A, Uchida H. Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. Eur Psychiatry. 2017 Oct;46:42-47

Palijan TŽ, Kovačević D, Vlastelica M, Dadić-Hero E, Sarilar M. Quality of Life of Persons Suffering from Schizophrenia, Psoriasis and Physical Disabilities. Psychiatr Danub. 2017 Mar;29(1):60-65

Suvisaari J, Keinänen J, Eskelinen S, Mantere O. Diabetes and Schizophrenia. Curr Diab Rep. 2016 Feb;16(2):16

Hettige NC, Nguyen TB, Yuan C, Rajakulendran T, Baddour J, Bhagwat N, Bani-Fatemi A, Voineskos AN, Mallar Chakravarty M, De Luca V. Classification of suicide attempters in schizophrenia using sociocultural and clinical features: A machine learning approach. Gen Hosp Psychiatry. 2017 Jul;47:20-28

Huot P. 5-HT2A receptors and Parkinson's disease psychosis: a pharmacological discussion.. Neurodegener Dis Manag. 2018 Dec;8(6):363-365

Zhi X, Cai L, Guo N, Liu X. Discussion on Brain Structure and Function in Schizophrenia by Multimodal Magnetic Resonance Imaging. J Med Syst. 2019 Mar 1;43(4):89

Wu D, Jiang T. Schizophrenia-related abnormalities in the triple network: a meta-analysis of working memory studies. Brain Imaging Behav. 2019 Mar 1. doi: 10.1007/s11682-019-00071-1

Buckner, R. L.; Andrews-Hanna, J. R.; Schacter, D. L. The Brain's Default Network: Anatomy, Function, and Relevance to Disease. Annals of the New York Academy of Sciences. 2008, 1124 (1): 1–38.

Zhuo C, Zhu J, Wang C, Qu H, Ma X, Tian H, Liu M, Qin W. Brain structural and functional dissociated patterns in schizophrenia. BMC Psychiatry. 2017 Jan 31;17(1):45

Fakhoury M. Could cannabidiol be used as an alternative to antipsychotics? J Psychiatr Res. 2016 Sep;80:14-21

Hensala JD, Epstein LJ, Blacker KH. LSD and psychiatric inpatients. Arch Gen Psychiatry. 1967 May;16(5):554-9.

Schneier F, Siris S, A Review of Psychoactive Substance Use and Abuse in Schizophrenia: Patterns of Drug Choice. The Journal of Nervous and Mental Disease 1987; 175(11):641-652, NOVEMBER 1987

Hambrecht M, Häfner H, Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996 Dec 1;40(11):1155-63.

Addington J, Addington D. Effect of substance misuse in early psychosis. Br J Psychiatry Suppl. 1998;172(33):134-6.

Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. Psychol Med. 1974 Aug;4(3):255-61.

Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991 Feb;148(2):224-30.

Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch Gen Psychiatry. 1982 Feb;39(2):141-7.

Walter M, Denier N, Vogel M, Lang UE. Effects of psychoactive substances in schizophrenia -- findings of structural and functional neuroimaging. Curr Top Med Chem. 2012;12(21):2426-33.

Becker C. G, Dubin T. Activation of factor XII by tobacco glycoprotein. J Exp Med. 1977 Aug 1; 146(2): 457–467.

O'Connor RJ, Schneller LM, Caruso RV, Stephens WE, Li Q, Yuan J, Fong GT. Toxic metal and nicotine content of cigarettes sold in China, 2009 and 2012. Tob Control. 2015 Nov;24 Suppl 4:iv55-9

Ferri E.S, Christiansen H. Lead-210 in tobacco and cigarette smoke. Public Health Rep. 1967 Sep; 82(9): 828–832.

Iwai T, Chiba K, Narukawa T. Arsenic Speciation and Cadmium Determination in Tobacco Leaves, Ash and Smoke. Anal Sci. 2016;32(9):957-62.

Ehlinger DG, Commons KG, Cav1.2 L-type calcium channels regulate stress coping behavior via serotonin neurons. Neuropharmacology, 2019 Jan;144:282-290

Green M.J, Girshkin L, Teroganova N, Quidé Y, Stress, Schizophrenia and Bipolar Disorder. Behavioral Neurobiology of Stress-related Disorders, 2014;18:217-35

Pugliese V, Bruni A, Carbone E. A, Calabrò G, Cerminara G, Sampogna G, Luciano M, SteardoJr L, Fiorillo A, Garcia C. S, De Fazio P, Maternal stress, prenatal medical illnesses and obstetric complications: Risk factors for schizophrenia spectrum disorder, bipolar disorder and major depressive disorder. Psychiatry Research, 2019 Jan;271:23-30.

Huang H, Dong M, Zhang L, Zhong BL, Ng CH, Ungvari GS, Yuan Z, Meng X, Xiang YT, Psychopathology and extrapyramidal side effects in smoking and non-smoking patients with schizophrenia: Systematic review and meta-analysis of comparative studies.’ Progress in Neuropsychopharmacology & Biological Psychiatry 2019 Jun 8;92:476-482

Wilson SM, Thompson AC, Currence ED, Thomas SP, Dedert EA, Kirby AC, Elbogen EB, Moore SD, Calhoun PS, Beckham JC; ‘Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia.‘ Behavior therapy. 2019 Mar;50(2):395-409

Underner M , Perriot J , Peiffer G , Harika-Germaneau G, Jaafari N ‘’Why stopping smoking is difficult in patients suffering from schizophrenia? How better to take care of them?‘’ Revue medicale de Liege. 2019 Jan;74(1):23-27

Drożak J, Bryła J. Dopamine: not just a neurotransmiter Postepy Hig Med Dosw. (online), 2005; 59: 405-420

Frątczak A, Kula K, Rabe-Jabłońska J, Strzelecki D, Modulation of the cholinergic system function in the treatment of schizophrenia – today and tomorrow. PSYCHIATR. PSYCHOL. KLIN. 2013, 13 (2), p. 108–115

Lucatch Aliya M., Lowe Darby J. E., Clark Rachel C., Kozak Karolina, George Tony P. Neurobiological Determinants of Tobacco Smoking in Schizophrenia , Frontiers in Psychiatry Vol.9 Y 2018 PS 672

Šagud M, Vuksan-ûusa B, SMOKING IN SCHIZOPHRENIA: AN UPDATED REVIEW Psychiatria Danubina, 2018; Vol. 30, Suppl. 4, pp S216-223

Evins A. E, Cather C, Laffer A, Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harvard review of psychiatry 2015; 23(2), 90–98.

Mallet, J., Le Strat, Y., Schürhoff, F. et al. Eur Arch Psychiatry Clin Neurosci (2019) 269: 449.

Sobkowiak R, Lesicki A, Absorption, metabolism and excretion of nicotine in humans. Postępy biochemii 2013; 59. 33-44.